1. Home
  2. VGZ vs ALLO Comparison

VGZ vs ALLO Comparison

Compare VGZ & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$1.99

Market Cap

229.7M

Sector

N/A

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.48

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
ALLO
Founded
1983
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
229.7M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
VGZ
ALLO
Price
$1.99
$1.48
Analyst Decision
Strong Buy
Buy
Analyst Count
1
11
Target Price
$3.00
$8.67
AVG Volume (30 Days)
1.2M
2.4M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.86
52 Week High
$2.46
$3.78

Technical Indicators

Market Signals
Indicator
VGZ
ALLO
Relative Strength Index (RSI) 62.20 64.66
Support Level $1.89 $1.30
Resistance Level $2.03 $1.49
Average True Range (ATR) 0.12 0.10
MACD 0.04 0.02
Stochastic Oscillator 90.21 97.72

Price Performance

Historical Comparison
VGZ
ALLO

About VGZ Vista Gold Corp

Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects for gold production or value adding strategic transactions. The Company has one reportable segment: Australia. The Australia segment conducts exploration, development, care and maintenance activities at Vista's asset, the Mt Todd gold project in Northern Territory, Australia.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: